CL2021003414A1 - Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados - Google Patents

Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados

Info

Publication number
CL2021003414A1
CL2021003414A1 CL2021003414A CL2021003414A CL2021003414A1 CL 2021003414 A1 CL2021003414 A1 CL 2021003414A1 CL 2021003414 A CL2021003414 A CL 2021003414A CL 2021003414 A CL2021003414 A CL 2021003414A CL 2021003414 A1 CL2021003414 A1 CL 2021003414A1
Authority
CL
Chile
Prior art keywords
antibodies
tissue factor
conjugates
related methods
factor drugs
Prior art date
Application number
CL2021003414A
Other languages
English (en)
Spanish (es)
Inventor
Jan-Willem Theunissen
Allen G Cai
Thi-Sau Migone
Original Assignee
Zymeworks Inc
Iconic Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74100836&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2021003414(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zymeworks Inc, Iconic Therapeutics Inc filed Critical Zymeworks Inc
Publication of CL2021003414A1 publication Critical patent/CL2021003414A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CL2021003414A 2019-07-03 2021-12-20 Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados CL2021003414A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962870644P 2019-07-03 2019-07-03

Publications (1)

Publication Number Publication Date
CL2021003414A1 true CL2021003414A1 (es) 2022-09-09

Family

ID=74100836

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2021003414A CL2021003414A1 (es) 2019-07-03 2021-12-20 Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
CL2024003094A CL2024003094A1 (es) 2019-07-03 2024-10-14 Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados.

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2024003094A CL2024003094A1 (es) 2019-07-03 2024-10-14 Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados.

Country Status (21)

Country Link
US (1) US20220257789A1 (https=)
EP (1) EP3994150A4 (https=)
JP (1) JP7709636B2 (https=)
KR (1) KR20220029724A (https=)
CN (1) CN114222752B (https=)
AR (1) AR119346A1 (https=)
AU (1) AU2020299398C9 (https=)
BR (1) BR112021025720A2 (https=)
CA (1) CA3141428A1 (https=)
CL (2) CL2021003414A1 (https=)
CO (1) CO2022001083A2 (https=)
CR (1) CR20220047A (https=)
DO (1) DOP2021000268A (https=)
EA (1) EA202193309A1 (https=)
EC (1) ECSP22007981A (https=)
IL (1) IL289138A (https=)
MX (1) MX2021015974A (https=)
PE (1) PE20221004A1 (https=)
PH (1) PH12021553289A1 (https=)
TW (1) TWI879780B (https=)
WO (1) WO2021003399A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3735271A4 (en) 2018-01-04 2022-06-15 Iconic Therapeutics, Inc. ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
TW202342517A (zh) * 2022-01-12 2023-11-01 美商艾康尼醫療有限責任公司 使用抗組織因子抗體之炎性疾病治療
AU2023225240A1 (en) * 2022-02-24 2024-09-05 Evopoint Biosciences Co., Ltd. Antibody, and drug conjugate and use thereof
TW202345906A (zh) * 2022-03-09 2023-12-01 美商艾克塞里克斯公司 以抗組織因子抗體藥物結合物治療實體腫瘤之方法
US20250276077A1 (en) * 2022-04-05 2025-09-04 Immunome, Inc. Epha2 antibodies
CN116143929B (zh) * 2023-02-03 2023-08-01 北京基科晟斯医药科技有限公司 抗重组人凝血因子VIIa-Fc融合蛋白的抗体及其应用
CN116789837B (zh) * 2023-03-24 2024-02-23 山西纳安生物科技股份有限公司 一种抗组织因子人源化抗体及制备的抗体偶联药物和应用
CN118772282A (zh) * 2023-04-10 2024-10-15 复旦大学 靶向组织因子的纳米抗体及偶联物的制备方法和用途
TW202448934A (zh) * 2023-04-28 2024-12-16 大陸商江蘇恆瑞醫藥股份有限公司 抗tf抗體和抗tf抗體-藥物偶聯物及其醫藥用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6055404B2 (ja) * 2010-06-15 2016-12-27 ゲンマブ エー／エス 組織因子に対するヒト抗体薬物結合体
AU2015318556C1 (en) * 2014-09-17 2021-01-07 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
CN107708733B (zh) * 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
EP3672990A1 (en) * 2017-08-25 2020-07-01 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
IL274122B2 (en) * 2017-11-02 2024-09-01 Genmab As Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
MX2020005473A (es) * 2017-11-27 2020-08-27 Purdue Pharma Lp Anticuerpos humanizados que se dirigen al factor tisular humano.
EP3735271A4 (en) * 2018-01-04 2022-06-15 Iconic Therapeutics, Inc. ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY DRUG CONJUGATES AND RELATED METHODS
TWI841554B (zh) * 2018-03-21 2024-05-11 丹麥商珍美寶股份有限公司 以鉑為主之劑與抗組織因子抗體－藥物共軛物的組合治療癌症之方法
MX2022015375A (es) * 2020-06-29 2023-01-16 Genmab As Conjugados de farmaco-anticuerpo anti-factor de tejido y su uso en el tratamiento de cancer.

Also Published As

Publication number Publication date
CO2022001083A2 (es) 2022-05-20
EP3994150A1 (en) 2022-05-11
KR20220029724A (ko) 2022-03-08
AR119346A1 (es) 2021-12-09
IL289138A (en) 2022-02-01
JP7709636B2 (ja) 2025-07-17
ECSP22007981A (es) 2022-05-31
TWI879780B (zh) 2025-04-11
EP3994150A4 (en) 2023-08-02
WO2021003399A1 (en) 2021-01-07
PH12021553289A1 (en) 2022-08-01
EA202193309A1 (ru) 2022-03-28
DOP2021000268A (es) 2022-08-15
CA3141428A1 (en) 2021-01-07
BR112021025720A2 (pt) 2022-06-21
US20220257789A1 (en) 2022-08-18
CR20220047A (es) 2022-06-23
MX2021015974A (es) 2022-04-26
AU2020299398C9 (en) 2026-01-22
AU2020299398A1 (en) 2022-02-24
JP2022538908A (ja) 2022-09-06
AU2020299398C1 (en) 2025-10-02
PE20221004A1 (es) 2022-06-15
CN114222752B (zh) 2025-11-14
CL2024003094A1 (es) 2025-02-07
TW202116357A (zh) 2021-05-01
CN114222752A (zh) 2022-03-22

Similar Documents

Publication Publication Date Title
CO2022001083A2 (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
MX2020007077A (es) Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2020002666A (es) Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato.
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
MX2023009205A (es) Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
MX2019010848A (es) Composiciones y procedimientos para el tratamiento del cancer.
MX2020011554A (es) Composiciones y metodos relacionados con conjugados de farmacos de anticuerpo anti grupo de diferenciacion 19 (cd19).
CO6382188A2 (es) Anticuerpos monoclonales que se unen al hgm-csf y composiciones medicas que los comprenden
MX2018010562A (es) Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso.
ECSP19044625A (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
ECSP22010121A (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
MX2022014231A (es) Conjugados de anticuerpo-farmaco que se enfocan a la uparap.
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
CL2025001398A1 (es) Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos
MX2020010110A (es) Conjugados de farmacos de agentes de union monoclonales de cmet, y usos de los mismos.
CO2024007413A2 (es) Conjugados peptídicos de inhibidores de tubulina peptídica como agentes terapéuticos
CL2023000099A1 (es) Tratamiento de enfermedades inflamatorias con anticuerpos anti-factor tisular
CL2023003905A1 (es) Conjugados novedosos que comprenden fosfoantígenos y su uso terapéutico
UY38265A (es) Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
CL2023002992A1 (es) Anticuerpos anti-c-met y conjugados de anticuerpo-fármaco
MX2021014729A (es) Metodos y composiciones para tratar enfermedades autoinmunitarias.
WO2019089594A8 (en) Combination treatment with antibody-drug conjugates and cytarabine
EA202091631A1 (ru) Антитела к тканевому фактору, конъюгаты антитело-лекарственное средство и связанные способы
CR20140095A (es) Un conjugado citotóxico ca6 antigeno-específico y métodos para utilizar el mismo